Research
Hormonal
Anti-TNF-alpha therapies (e.g., infliximab) fail to improve insulin sensitivity in type 2 diabetes patients, whereas they successfully reduce insulin resistance in patients with high-grade inflammatory diseases like rheumatoid arthritis.
Taking anti-inflammatory drugs like TNF inhibitors will not fix insulin resistance if your primary issue is obesity or metabolic syndrome. These drugs work for autoimmune conditions, but for metabolic health, focusing on reducing saturated fats and weight is the effective path.
StrongQualifiesHIGH confidence
Considering anti-TNF antibodies, the results are disappointing as many clinical trials in type 2 diabetic patients have failed to demonstrate an effect of TNF neutralization on insulin sensitivity... On the other hand, in patients with high grade inflammatory diseases such as rheumatoid arthritis and ankylosing spondylitis, anti-TNF therapy has been successfully associated with reduction in insulin resistance and metabolic syndrome components.
Why this rating
Based on multiple cited clinical trials showing failure in T2D and success in RA.
Source
Molecular Targets Related to Inflammation and Insulin Resistance and Potential Interventions
Sandro Massao Hirabara et al. · Journal of Biomedicine and Biotechnology · 2012
DOI 10.1155/2012/379024
narrative_reviewCited 177×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Saturated fatty acids (SFAs) activate Toll-like receptor 4 (TLR4) in skeletal muscle and adipose tissue, triggering IKK and JNK kinases that phosphorylate IRS proteins on serine residues, thereby blocking insulin signaling and causing insulin resistance.Good
- Activation of G-protein coupled receptor 120 (GPR120) by n-3 fatty acids (DHA, alpha-linolenic acid) attenuates the production of pro-inflammatory cytokines (TNF-alpha, IL-6, MCP-1) and prevents obesity-induced glucose intolerance and insulin resistance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →